Key terms
About ASND
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ASND news
Apr 12
9:41am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
Mar 27
5:27pm ET
Ascendis Pharma Updates Share Capital Structure
Mar 21
8:33am ET
Ascendis, MoonLake Immunotherapeutics removed from Best Ideas List at Wedbush
Mar 15
7:20am ET
Ascendis Pharma price target raised to $260 from $196 at Wells Fargo
Mar 01
7:06am ET
Analysts’ Top Healthcare Picks: Xenon (XENE), Ascendis Pharma (ASND)
Feb 22
7:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 20
8:41am ET
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), IQVIA Holdings (IQV) and Ascendis Pharma (ASND)
Feb 09
1:02am ET
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BridgeBio Pharma (BBIO)
Feb 09
1:01am ET
Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
Feb 08
7:48am ET
Ascendis Pharma price target raised to $225 from $207 at Wedbush
Feb 08
7:47am ET
Oppenheimer Sticks to Their Hold Rating for Ascendis Pharma (ASND)
Feb 08
6:56am ET
Buy Rating Affirmed for Ascendis Pharma on Strong Market Potential and Technological Edge
Feb 08
6:55am ET
Ascendis Pharma: Strong Buy on Robust Sales and Innovative Pipeline
Feb 08
6:39am ET
Ascendis Pharma price target raised to $182 from $146 at Citi
Feb 07
9:40pm ET
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Ascendis Pharma (ASND)
Feb 07
7:55pm ET
Buy Rating Affirmed for Ascendis Pharma as Analyst Anticipates TransCon PTH Approval and Steady Financial Growth
Jan 29
8:51pm ET
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Sarepta Therapeutics (SRPT)
No recent press releases are available for ASND
ASND Financials
Key terms
Ad Feedback
ASND Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ASND Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
